Pituitary adenylate cyclase-activating polypeptide induces cAMP production independently from vasoactive intestinal polypeptide in osteoblast-like cells.

Suzuki A, Kotoyori J, Oiso Y, Kozawa O

Cellular signalling1 Jan 1994Cited by 12 (Europe PMC)

PMID7912096DOI10.1016/0898-6568(94)90056-6PepBankPUB-07912096

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

4 results from studies that gave the peptide. No result from this study comes from people.

01LabIn vitro (cells)Activity measurement
In osteoblast-like MC3T3-E1 cells, VIP stimulated cAMP accumulation in a dose-dependent manner.
In plain wordsIn lab-grown bone-forming cells, VIP raised cAMP, an internal signal molecule, in a dose-dependent way.
Peptide
Vasoactive intestinal peptide (VIP, aviptadil)
Outcome
IncreasecAMP accumulation
Study
n: not reported in source
osteoblast-like MC3T3-E1 cells
Outcome group
Receptor activity and mechanism · Musculoskeletal
Studied dose
1 nM to 0.1 microMAs given in this study.
Source sentences
Summary
VIP also stimulated cAMP accumulation dose-dependently between 1 nM and 0.1 microM.
1 context sentence(design, population, supporting numbers)
Summary · context
In this study, we investigated the effects of PACAP on cAMP accumulation, phosphoinositide hydrolysis and Ca2+ influx in osteoblast-like MC3T3-E1 cells, compared with those of vasoactive intestinal polypeptide (VIP), which shows a considerable homology with PACAP in the N-terminal sequence.
Report a problemFND-0791209601
02LabIn vitro (cells)Activity measurement
In MC3T3-E1 cells, VIP stimulated cAMP accumulation with an EC50 of 30 nM, less potent than PACAP.
In plain wordsIn lab-grown bone-forming cells, VIP raised cAMP less potently than PACAP did.
Peptide
Vasoactive intestinal peptide (VIP, aviptadil)
Outcome
Not applicablecAMP accumulation potency (EC50) versus PACAP
Study
n: not reported in source
osteoblast-like MC3T3-E1 cells
Comparator
PACAP
Outcome group
Receptor activity and mechanism · Musculoskeletal
Studied dose
Dose not stated
Measurements
EC50
30 nM
VIP, cAMP accumulation, MC3T3-E1 cells
Source sentences
Summary
The effect of PACAP on cAMP accumulation (EC50 = 3 nM) was more potent than that of VIP (EC50 = 30 nM).
1 context sentence(design, population, supporting numbers)
Summary · context
In this study, we investigated the effects of PACAP on cAMP accumulation, phosphoinositide hydrolysis and Ca2+ influx in osteoblast-like MC3T3-E1 cells, compared with those of vasoactive intestinal polypeptide (VIP), which shows a considerable homology with PACAP in the N-terminal sequence.
Report a problemFND-0791209602
03LabIn vitro (cells)Mechanism
In MC3T3-E1 cells, VIP had little effect on the formation of inositol phosphates.
In plain wordsIn lab-grown bone-forming cells, VIP had little effect on inositol phosphate formation.
Peptide
Vasoactive intestinal peptide (VIP, aviptadil)
Outcome
No significant changeInositol phosphate formation
Study
n: not reported in source
osteoblast-like MC3T3-E1 cells
Outcome group
Receptor activity and mechanism · Musculoskeletal
Studied dose
Dose not stated
Source sentences
Summary
Either PACAP or VIP had little effect on the formation of inositol phosphates and Ca2+ influx in these cells.
1 context sentence(design, population, supporting numbers)
Summary · context
In this study, we investigated the effects of PACAP on cAMP accumulation, phosphoinositide hydrolysis and Ca2+ influx in osteoblast-like MC3T3-E1 cells, compared with those of vasoactive intestinal polypeptide (VIP), which shows a considerable homology with PACAP in the N-terminal sequence.
Report a problemFND-0791209605
04LabIn vitro (cells)Mechanism
In MC3T3-E1 cells, VIP had little effect on Ca2+ influx.
In plain wordsIn lab-grown bone-forming cells, VIP had little effect on calcium entry.
Peptide
Vasoactive intestinal peptide (VIP, aviptadil)
Outcome
No significant changeCa2+ influx
Study
n: not reported in source
osteoblast-like MC3T3-E1 cells
Outcome group
Receptor activity and mechanism · Musculoskeletal
Studied dose
Dose not stated
Source sentences
Summary
Either PACAP or VIP had little effect on the formation of inositol phosphates and Ca2+ influx in these cells.
1 context sentence(design, population, supporting numbers)
Summary · context
In this study, we investigated the effects of PACAP on cAMP accumulation, phosphoinositide hydrolysis and Ca2+ influx in osteoblast-like MC3T3-E1 cells, compared with those of vasoactive intestinal polypeptide (VIP), which shows a considerable homology with PACAP in the N-terminal sequence.
Report a problemFND-0791209606

Studies that did not test the peptide alone2

In this study, Vasoactive intestinal peptide (VIP, aviptadil) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Vasoactive intestinal peptide (VIP, aviptadil).

05LabNot a test of Vasoactive intestinal peptide (VIP, aviptadil) aloneIn vitro (cells)Activity measurement
In MC3T3-E1 cells, cAMP accumulation stimulated by PACAP combined with VIP was additive.
In plain wordsIn lab-grown bone-forming cells, PACAP and VIP together raised cAMP by the sum of their separate effects.
Peptide
Vasoactive intestinal peptide (VIP, aviptadil)
Outcome
Not applicablecAMP accumulation with PACAP and VIP combined
Study
n: not reported in source
osteoblast-like MC3T3-E1 cells
Outcome group
Receptor activity and mechanism · Musculoskeletal
Source sentences
Summary
The cAMP accumulation stimulated by a combination of PACAP (3 nM) and VIP (30 nM) was additive.
1 context sentence(design, population, supporting numbers)
Summary · context
In this study, we investigated the effects of PACAP on cAMP accumulation, phosphoinositide hydrolysis and Ca2+ influx in osteoblast-like MC3T3-E1 cells, compared with those of vasoactive intestinal polypeptide (VIP), which shows a considerable homology with PACAP in the N-terminal sequence.
In this study, Vasoactive intestinal peptide (VIP, aviptadil) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Vasoactive intestinal peptide (VIP, aviptadil).
Report a problemFND-0791209603
06LabNot a test of Vasoactive intestinal peptide (VIP, aviptadil) aloneIn vitro (cells)Mechanism
In MC3T3-E1 cells, a VIP receptor antagonist markedly inhibited the VIP-induced cAMP accumulation.
In plain wordsIn lab-grown bone-forming cells, a VIP receptor blocker strongly reduced the cAMP rise caused by VIP.
Peptide
Vasoactive intestinal peptide (VIP, aviptadil)
Outcome
DecreaseEffect of a VIP receptor antagonist on VIP-induced cAMP
Study
n: not reported in source
osteoblast-like MC3T3-E1 cells
Comparator
No antagonist
Outcome group
Receptor activity and mechanism · Musculoskeletal
Source sentences
Summary
[Lys1, Pro2,5, Arg3,4, Tyr6]-VIP, and antagonist for the VIP receptor which markedly inhibited the VIP-induced cAMP accumulation, had little effect on the PACAP-induced cAMP accumulation.
1 context sentence(design, population, supporting numbers)
Summary · context
In this study, we investigated the effects of PACAP on cAMP accumulation, phosphoinositide hydrolysis and Ca2+ influx in osteoblast-like MC3T3-E1 cells, compared with those of vasoactive intestinal polypeptide (VIP), which shows a considerable homology with PACAP in the N-terminal sequence.
In this study, Vasoactive intestinal peptide (VIP, aviptadil) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Vasoactive intestinal peptide (VIP, aviptadil).
Report a problemFND-0791209604

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 12:58 UTC
Study results updated
Version 1
9 Oct 2026, 12:41 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.